Treatment of Chronic Central Serous Chorioretinopathy With Open-Label Anecortave Acetate

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

Investigation to evaluate Anecortave Acetate in the treatment of chronic central serous chorioretinopathy

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Manhattan Eye, Ear & Throat Hospital
• Collaborators: Alcon Research; LuEsther T. Mertz Retinal Research Center
• Treatments: Anecortave; Hydrocortisone

Criteria

Inclusion Criteria:

1. A male or female, of any race with clinical signs of chronic CSC:Evidence of chronic central serous chorioretinopathy and clinical/angiographic findings typical of the disease of greater than 6 months duration. Chronic central serous chorioretinopathy can be defined on the basis of two factors: 1) persistence of the detachment for more than 6 months and 2) chronic recurrent acute detachments with widespread decompensation of the retinal pigment epithelium

2. Patient must have best corrected ETDRS visual acuity between 20/40 and 20/320 in the Study Eye and visual acuity of 20/800 or better Fellow Eye

3. Patient must be willing, able to comply with the protocol, and provide informed consent.

Exclusion Criteria:

1. Patient with tears in retinal pigment epithelium.

2. Patient with significantly compromised visual acuity in the study eye due to concomitant ocular conditions.

3. Patients who have undergone intraocular surgery within last 2 months or capsulotomy within last month in study eye

4. Patient participating in any other investigational drug study.

5. Inability to obtain photographs to document CNV (including difficulty with venous access)

6. Patient with significant liver disease or uremia.

7. Patient with known adverse reaction to indocyanine green or iodine.

8. Patient is pregnant or nursing.